

Q-linea shares progress on roll-out in the Middle East

Q-linea AB (publ) (OMX: QLINEA) today shared updates on the progress of the introduction of ASTar® System in the GCC region.

During the first week of February, ASTar instrument was on display in the booth of the AMICO Group at Medlab Middle East in Dubai, United Arab Emirates. With over 28,000 visitors and close to 900 exhibiting companies in 2024, it is the premier event for introducing new technologies for medical laboratories in Asia, Africa and the GCC region. Supported by colleagues from Q-linea, the AMICO team performed multiple demos to representatives from private and public hospitals, and ASTar was very well received.

As a continuation of the business development strategy in the Region, AMICO will host a Sepsis Management Day on February 19 in Riyadh, Saudi Arabia. The roll-out plan combines educating healthcare professionals about the benefits of rapid AST and its role in patient care with product evaluations at select hospitals.

"We are very pleased with the reception of ASTar at Medlab and impressed with AMICO's professionalism in navigating the multi-jurisdictional region quickly and effectively which is already resulting in concrete customer conversations," said Franco Pellegrini, VP Sales EMEA at Q-linea.

Sherif Harydi, Business Development Director at AMICO Group, said: "We are very pleased by the reception ASTar System has received in the market so far. We look forward to working together with the Q-linea team to introduce ASTar in our region through events and product evaluations."

Previous communication, Sept 27, 2024: https://qlinea.com/mfn_news/q-linea-enters-the-middle-east-region-through-partnership-with-amico-group/?ln=en

For more information, please contact:

Stuart Gander, President & CEO, Q-linea **Stuart.Gander@qlinea.com** +1 857 409 7463

Christer Samuelsson, CFO /IR, Q-linea AB Christer.Samuelsson@qlinea.com +46 (0) 70-600 15 20



About Q-linea

Q-linea's rapid AST system, ASTar[®], accelerates and simplifies the time-sensitive workflows faced during the treatment of patients with bloodstream infections and sepsis. Hospitals use ASTar to vastly reduce the time to optimal antimicrobial therapies and ensure that patients receive the correct treatments sooner — when time matters most. We are helping to create sustainable healthcare, now and in the future, and safeguard the effectiveness of antibiotics for generations to come.

Q-linea is headquartered in Uppsala, Sweden and has regional offices in Italy and the USA, with partnerships worldwide.

ASTar Instrument and ASTar BC G- Consumable kit are CE-IVD marked and FDA 510(k) cleared. For more information, please visit www.qlinea.com

Attachments

Q-linea shares progress on roll-out in the Middle East